Methods of Treating Cancer of the Central Nervous System; V.I. Teichberg, and A. Ruban; Yeda Research & Development, USA; U.S. Patent # 10,159,717, December 25, 2018.
In the last few years, an ever-increasing body of data have suggested that glutamate (Glu), the major excitatory neurotransmitter in the brain, plays a crucial role in the growth of malignant gliomas, their invasiveness and ability to destroy neighboring brain tissue. The present invention provides the method of administering to the subject a therapeutically effective amount of an agent, which reduces the blood glutamate levels. Thus, it enhances brain to blood glutamate efflux and thereby treats the cancer of the central nervous system. The patent claims a chemotherapeutic agent for treating glioma which can cross the blood brain barrier and at least one glutamate modifying enzyme capable of reducing blood glutamate levels and enhancing brain to blood glutamate efflux. The said glutamate modifying enzyme is lyophilized, emulsified, encapsulate or formulated as a tablet, pill, dragee or capsule.
Stabilized Formulations of CNS Compounds; R.K. Chang, M.L. Vieira, L. Liang, P.P. Bhatt, A.B. Huang, and. S.V. Patel; Supernus Pharmaceuticals, USA, U.S. Patent # 10,149,853; December 11, 2018.
This patent provides a formulation of molindone having superior stability. The immediate release dosage form of molindone is marketed as Moban®, which extensively and rapidly metabolized with an oral dose plasma elimination half-life of about two hours. It is taken three to four times daily with a typical maintenance dose. The patent claims the pharmaceutical formulation comprising molindone as single active pharmaceutical ingredient and having modified release comprising at least one release-controlling polymer and at least one stabilizer. Optionally an additional formulation was developed comprising molindone in an immediate release, extended release or delayed release formulation for once a day or twice a day administration.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
Gold Complexes of Alkylated Phosphines; S.S. Al-Jaroudi, A. Alhoshani, M. Altaf, and A.A. Isab; King Fahd University of Petroleum and Minerals, Saudi Arabia; U.S. Patent # 10,144,749; December 4, 2018.
Present invention discloses a pharmaceutical composition and a method of treating cancer. The pharmaceutical composition uses complexes of gold and chemotherapeutic agents and inactive carriers. The method disclosed here to treat cancer involves the delivery of the above stated pharmaceutical composition. The effect of the composition is measured by analyzing mutation before and after the administration. This mutation is calculated by measuring the concentration of substances produced in the body by ELISA assay. These substances are known as biomarkers. A decrease or increase in responses generated by biomarkers may indicate that a disease is being treated. Examples of biomarkers used to detect the presence of a disease or any other pathological condition in the body include but are not limited to BRCA1, BRCA-2 and Ki67.
Multi-Ported Drug Delivery Device Having Multi-Reservoir Cartridge System; F. Amirouche and M.L. Cantwell; Picolife Technologies, LLC; U.S. Patent # 10,130,759; November 20, 2018.
The present invention relates to a multi-ported drug delivery device having a cartridge system with multiple interconnected reservoirs that are independently actuated for delivery of medicament(s). The device has a pump driver system, a cartridge system, a cannula and an insertion mechanism, and a plurality of conduits. Different reservoirs contain different medicaments. For example, to treat diabetes, the reservoirs may contain insulin and glucagon. The delivery of medicaments can be at a controlled and continuous rate for a pre-determined or user-defined period of time. Alternatively, the delivery of medicament can also be at a programmable rate that is regulated by the patient. The device can deliver micro-doses of medicaments.
Child-Resistant Blister Package; K.F. Trombley, K.L.T. Chan, I. Lafosse-Marin, J.R. Morosey, Jr., K.M. Sanchez, and K.L. Schmeichel; Th e Procter & Gamble Company, USA; U.S. Patent # 10,130,557; November 20, 2018.
Medicines are generally packaged in bottles, cartons, blister packages, or other suitable packaging prior to use. Child-resistant features can be added to reduce the risk of a small child accessing and ingesting the medication. This patent is particularly directed to child-resistant blister packages. Child-resistant features require a combination of dexterity (special hand skill), strength, and intellect to operate. The child-resistant blister package has a protection layer with a top face, a bottom face and a periphery. It has a blister layer with one or more cavities and an access layer with a top face, a bottom face, and a periphery. The bottom face of the access layer has a line of weakness that allows the unit dose to be removed from the cavity in one-step by applying a force to the top of the cavity and pressing the unit dose through the line of weakness. The bottom face of the protection layer and the top face of the access layer are permanently joined along the entire periphery of the package. The blister package can also contain a tear resistant layer.
Drug Device Configured for Wireless Communication; R.L. Altschul, N.D. Theise, R.A. Ene, M. Rapkin, and R. O’Brien; Pop Test Abuse Deterrent Technology, USA, U.S. Patent # 10,137,288; November 27, 2018.
The inventors of the device describe it as a perfected “Smart Pill”, which is able to prevent deaths by overdose of medicines. It is also claimed to help decrease misuse and abuse of harmful drugs. The smart pills disclosed in the patent are capsules which have electrical sensors. These sensors send signals to the pharmacist or the prescribing doctor. Through these signals it monitors the time and duration of the medicine taken by patient. If the patient accidently takes another capsule, the first capsule inside patient will sense the presence of another capsule and built-in sensor will not allow release of drug from the second. Through this technology it may avoid unintentional overdosing. The smart pills can have a variety of sensors like electronic, biological, chemical, harmonic and digital. Through these sensors, smart pills can be programmed to perform tasks such as preventing drug-drug interactions, drugs of abuse, dose dumping by alcohol consumption and teratogenic drugs during pregnancy.
Volatile Organic Compound Formulations Having Antimicrobial Activity; G.A. Strobel and B. Blatt; Ecoplanet Environmental LLC, USA; U.S. Patent # 10,117,841; November 6, 2018.
This patent invention includes novel chemical formulations having antimicrobial activity and their methods of use. The fraction of human, animal and industrial waste that is untreated gives rise to bacterial and microbial growth, which poses a threat to health. Safer and effective means for treating microbe-laden surfaces in medical or hospital environments and for treating agricultural crops for unwanted microbial growth are needed, in addition, reducing the unwanted odors produced in the breakdown of fecal matter in industrial farming operations is of utmost importance. The antimicrobial formulation invented in the patent is made of propanoic acid, iso-butyric acid, isoamyl hexanoates and a carrier selected from the group consisting of bentonite, zeolite and perlite. This formulation eff ectively reduces microorganisms and the eff ects of microbial outgrowth in a wide range of industrial settings, as well as in methods of human and animal waste treatment.